This AOP is open for adoption and licensed under the BY-SA license. The BY-SA license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
AOP: 117
Title
Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat)
Short name
Graphical Representation
Point of Contact
Contributors
- Charles Wood
- Evgeniia Kazymova
Coaches
OECD Information Table
OECD Project # | OECD Status | Reviewer's Reports | Journal-format Article | OECD iLibrary Published Version |
---|---|---|---|---|
1.26 | Under Development |
This AOP was last modified on May 26, 2024 20:39
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Activation, Androgen receptor | December 03, 2016 16:37 |
Increase, cell proliferation (hepatocytes) | January 06, 2021 16:21 |
Increase, Preneoplastic foci (hepatocytes) | September 16, 2017 10:16 |
Increase, hepatocellular adenomas and carcinomas | December 26, 2020 10:09 |
Activation, Androgen receptor leads to Increase, cell proliferation (hepatocytes) | December 03, 2016 16:38 |
Increase, cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes) | February 14, 2017 17:05 |
Increase, Preneoplastic foci (hepatocytes) leads to Increase, hepatocellular adenomas and carcinomas | February 15, 2017 10:20 |
Abstract
This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.
AOP Development Strategy
Context
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
MIE | 785 | Activation, Androgen receptor | Activation, Androgen receptor |
KE | 716 | Increase, cell proliferation (hepatocytes) | Increase, cell proliferation (hepatocytes) |
KE | 774 | Increase, Preneoplastic foci (hepatocytes) | Increase, Preneoplastic foci (hepatocytes) |
AO | 719 | Increase, hepatocellular adenomas and carcinomas | Increase, hepatocellular adenomas and carcinomas |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Network View
Prototypical Stressors
Life Stage Applicability
Taxonomic Applicability
Sex Applicability
Sex | Evidence |
---|---|
Male | |
Female |
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Evidence Assessment
Known Modulating Factors
Quantitative Understanding
Considerations for Potential Applications of the AOP (optional)
References
NTP (National Toxicology Program). (September 2010). Toxicology and Carcinogenesis Studies of Androstenedione in F344/N Rats and B6C3F1 Mice (Vol. NTP TR 560).